Tegatrabetan

Drug Profile

Tegatrabetan

Alternative Names: BC 2059

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator BetaCat Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Fibroma; Multiple myeloma

Most Recent Events

  • 12 Apr 2017 BetaCat Pharmaceuticals has patents pending for transducin β-like protein 1 inhibitors in European Union, Eastern Europe, India, China, Japan, and Canada
  • 12 Apr 2017 BetaCat Pharmaceuticals has patent protection for transducin β-like protein 1 inhibitors in South Korea, Mexico, New Zealand, Singapore, South Africa, Eurasia
  • 10 Feb 2017 BetaCat Pharmaceuticals plans clinical studies in Fibroma and Acute myeloid leukaemia in the first half of 2017 (BetaCat Pharmaceuticals pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top